Company: INSP
Filing Date: 2025-02-10
Form Type: 10-K
Source: 0001609550-25-000011
Chunk: 6

Company: Inspire Medical Systems, Inc.
Filing Date: 2025-02-10
Form: 10-K
Item: Item 9B
Chunk 6
---
Table of Contents

Item 9B.  Other Information.

(b) Adoption or Termination of Trading Arrangements by Directors and Executive Officers

NameTitleActionRule 10b5-1Adoption/Termination DateAggregate Number of Shares of Common Stock to be SoldExpiration DateShawn T McCormickDirectorTerminateNovember 1, 20241,050May 2, 2025Shawn T McCormickDirectorAdoptNovember 13, 20248,600August 15, 2025Richard J. BuchholzChief Financial OfficerAdoptNovember 13, 202415,000November 28, 2025Randall BanEVP Patient Access and Therapy DevelopmentAdoptNovember 13, 202425,000August 15, 2025Bryan PhillipsGeneral CounselAdoptNovember 27, 20246,152(1)September 30, 2025(1) This number includes shares of our common stock issuable pursuant to performance stock units (“PSU”) that may vest during the term of the 10b5-1 plan, subject to the achievement of certain performance conditions as set forth in the applicable PSU agreement. The actual number of PSUs that vest following the end of the applicable performance period, if any, and therefore the resulting shares of our common stock available for sale under the plan will depend on the attainment of the performance metrics. Also, shares of our common stock issuable pursuant to vested PSUs will be subject to tax withholding obligations that may reduce the net shares actually issued and, therefore, available for sale under the applicable plan; however, the maximum aggregate gross number of shares of our common stock included in the applicable plan is reported in this table without reduction for such future tax obligations and assuming maximum achievement of the performance conditions under the PSUs.

There were no other "Rule 10b5-1 trading arrangements" or "non-Rule 10b5-1 trading arrangements," as each term is defined in Item 408(a) of Regulation S-K, adopted, modified or terminated by the Company’s directors or "officers" (as defined in Rule 16a-1(f) of the Exchange Act) during the quarter ended December 31, 2024.